A Multicenter, Randomized, Double-Blind, Phase 2b Trial to Determine The Efficacy, Tolerability And Safety Of 3 Dose Regimens Of RDEA806 and Open-Label Efavirenz as Active Control in HIV 1-Infected, Antiretroviral Naïve Subjects
- Registry ID
- EUCTR2008-005113-21
- Source registry
- EUCTR
- Status
- Prematurely Ended
- Phase
- PHASE2
- Sponsor
- Ardea Biosciences, Inc.
- Start date
- 2008-10-08
- Completion date
- 2009-08-07
- Last update
- 2026-08-16
Conditions
Summary
Evaluate the antiviral activity at 24 weeks across 3 doses of RDEA806 (non-nucleoside reverse transcriptase inhibitor [NNRTI]) and the efavirenz regimen (proportion of subjects with human immunodeficiency virus ribonucleic acid (HIV RNA) < 50 copies/mL (intent-to treat [ITT]: non-completer [NC] = failure [F])
Locations
- , , Germany
- , , UK
- , , Poland
View on source registry